

Inhibition of A β ₄₂ oligomerization in yeast by a PICALM ortholog and certain FDA approved drugs

Sei-Kyoung Park¹, Kiira Ratia², Mariam Ba¹, Maria Valencik¹ and Susan W. Liebman^{1,3,*}

¹ Present address: Department of Biochemistry and Molecular Biology, University of Nevada, Reno, Reno, NV, USA.

² HTS facility, Research Resources Center, University of Illinois, Chicago, Chicago, IL 60612, USA.

³ Department of Biological Sciences, University of Illinois, Chicago, Chicago, IL 60607, USA.

* Corresponding Author: Susan W. Liebman, Department of Biochemistry and Molecular Biology, University of Nevada, Reno 1664 N. Virginia Street, Mail stop/330; Reno NV89557, USA; Tel (Office): +1 775 682 7338, Tel (Lab): +1 775 327 2251; Fax: +1 775 784 1419; E-mails: suel@uic.edu or sliebman@unr.edu

ABSTRACT The formation of small A β ₄₂ oligomers has been implicated as a toxic species in Alzheimer disease (AD). In strong support of this hypothesis we found that overexpression of Yap1802, the yeast ortholog of the human AD risk factor, phosphatidylinositol binding clathrin assembly protein (PICALM), reduced oligomerization of A β ₄₂ fused to a reporter in yeast. Thus we used the A β ₄₂-reporter system to identify drugs that could be developed into therapies that prevent or arrest AD. From a screen of 1,200 FDA approved drugs and drug-like small compounds we identified 7 drugs that reduce A β ₄₂ oligomerization in yeast: 3 antipsychotics (bromperidol, haloperidol and azaperone), 2 anesthetics (pramoxine HCl and dyclonine HCl), tamoxifen citrate, and minocycline HCl. Also, all 7 drugs caused A β ₄₂ to be less toxic to PC12 cells and to relieve toxicity of another yeast AD model in which A β ₄₂ aggregates targeted to the secretory pathway are toxic. Our results identify drugs that inhibit A β ₄₂ oligomers from forming in yeast. It remains to be determined if these drugs inhibit A β ₄₂ oligomerization in mammals and could be developed as a therapeutic treatment for AD.

INTRODUCTION

Alzheimer's disease (AD), a progressive and fatal brain disorder, is the most common form of dementia currently affecting more than 5 million Americans. Furthermore, more than 26 million people worldwide have some form of dementia.

With the increase in the age of the population, the number of AD patients is expected to triple by 2050 causing a staggering emotional and financial toll. Unfortunately, there is no prevention or satisfactory treatment to date.

To prevent or stop disease progression at an early stage, we need to attack the underlying causes of the disease. The major physical feature of AD is the accumulation of abnormally folded beta-amyloid (A β) and Tau in the brain. When A β ₄₂ is polymerized *in vitro* [1-4] or purified from *in vivo* animal models, post mortem brain [5, 6] or cerebrospinal fluid (CSF) tissue of AD patients [7, 8], small A β ₄₂ aggregates are found that differ in size and shape. Such small aggregates of the A β ₄₂ peptide (dimers, trimers, tetramers, etc.) appear to be neurotoxic because they trig-

ger abnormalities in neuronal excitation and synaptic plasticity, and inhibit hippocampal long-term potentiation [1, 2, 9-12]. Still, it remains to be determined if A β ₄₂ is a major cause of AD [13]. Nonetheless, there is evidence for a pathological role of A β oligomers on other protein oligomers in neurodegenerative conditions, such as Parkinson's disease [14], and prion diseases [15].

Many fundamental biological processes and pathways such as chaperone and protein remodeling, the ubiquitin proteasome system, secretion, vesicular trafficking, and autophagy, are highly conserved between yeast and human cells. Indeed, yeast models have become powerful tools for unraveling the molecular basis of complex human neurodegenerative diseases [16-19]. Treatment with A β ₄₂ oligomers formed *in vitro* or expression of A β ₄₂ oligomers *in vivo* affects the growth of yeast cells [20-24]. Also, a yeast model in which A β ₄₂ (referred as HDEL-A β ₄₂) is toxic was recently developed. Here, a *GAL1* promoter was used to express a *KAR2* signal sequence (*HDEL*) A β ₄₂ fusion protein. This A β ₄₂ fusion protein was directed to the secretory

doi: 10.15698/mic2016.02.476

Received originally: 01.08.2015;

in revised form: 03.12.2015,

Accepted 08.12.2015,

Published 20.01.2016.

Keywords: A β ₄₂ oligomerization, yeast, HTS, PICALM, Alzheimer.

Abbreviations:

AD - Alzheimer disease,

A β - beta-amyloid,

FDA - Food and Drug Administration agency,

HTS - high-throughput screening,

PGK - 3-phosphoglycerate kinase,

PICALM - phosphatidylinositol clathrin assembly lymphoid-myeloid leukemia,

RF - release factor,

TMR - tetramethylrhodamine.

pathway where it disrupted normal cellular endocytic trafficking, causing toxicity [24]. Importantly, overexpression of *YAP1802*, a yeast homolog of PICALM, rescued cells from this toxicity [24]. PICALM (phosphatidylinositol clathrin assembly lymphoid-myeloid leukemia) protein plays a key role in a clathrin-mediated endocytosis and genome-wide association studies identified single nucleotide polymorphisms in the gene of PICALM as genetic risk factors for late-onset AD [25, 26]. Furthermore, overexpressed PICALM protected primary rat cortical neurons and *C. elegans* from toxicity of extracellular aggregated Aβ₄₂ oligomers. In addition, PICALM affected Aβ₄₂ toxicity in a yeast

model in which the α-factor signal sequence was fused to Aβ₄₂, although here overexpression of PICALM enhanced toxicity [23]. While little is known about the contribution of PICALM to AD pathogenesis, these findings strongly support the hypothesis that Aβ₄₂ is associated with AD toxicity.

Yeast has been used to screen for chemical compounds that reduce aggregation or oligomerization of the Aβ peptide by assaying for the activity of reporters fused to Aβ [27, 28]. Previously, using a yeast Aβ₄₂ oligomerization model in which Aβ₄₂ was fused to the functional release factor (RF) domain of yeast translational termination factor, Sup35 [29], we screened for anti-Aβ₄₂ oligomer compounds




FIGURE 1: Effect of genetic modifiers of toxic HDEL-Aβ₄₂ on Aβ₄₂-RF oligomer formation and Aβ₄₂-MRF aggregates into toxic SDS-stable oligomers in yeast. (A) Overexpressed Yap1802 but not other previously described [24] HDEL-Aβ₄₂ modifiers dramatically enhanced the translational termination factor activity of Aβ₄₂-RF. Aβ₄₂-RF expressing cells (*CUP1::Aβ₄₂-RF*) lacking chromosomal *SUP35* were transformed with a plasmid carrying the indicated gene under control of the *GAL1* promoter. Ten-fold serial dilutions of transformants are shown on plasmid selective non-inducing media (SD-Ura); galactose plasmid selective media (SGal-Ura) to turn on each gene (↑ORF); +Ade medium containing copper to overexpress Aβ₄₂-RF (↑ORF ↑Aβ₄₂-RF); the identical -Ade medium SGal-Ura-Ade+Cu²⁺ (-Ade ↑ORF ↑Aβ₄₂-RF) to determine translational termination factor activity as read-through of the *ade1-14* nonsense mutant. The Aβ₄₂-RF overexpressed in cells was shown to have reduced translational termination factor activity as cells grew on -Ade due to aggregation of the fusion protein into small oligomers (Aβ₄₂-RF-e. v.). However, the translation termination factor activity was retained in yeast cells overexpressing Aβ₄₂m2-RF (Aβ₄₂ aggregation-deficient mutant) or YAP1802, due to the absence of oligomer formation, resulting in reduced growth on -Ade (Aβ₄₂m2-RF-e. v.). **(B)** Yap1802 suppression of Aβ₄₂-RF oligomerization by immunoblot analysis. Total cell lysates were prepared from 2 independent transformants of an Aβ₄₂-RF strain carrying *YAP1802* (+) or an empty vector (-) plasmid. Both Aβ₄₂-RF and YAP1802 were overexpressed (SGal-Ura-Ade+Cu²⁺) prior to lysis. Immunoblots were probed with anti-Sup35 RF to evaluate the level of oligomers and monomers. ↑Yap1802 indicates overexpression of *YAP1802*. The identification of bands as Aβ₄₂-RF dimers and monomers was determined by the estimated sizes of the bands in the immunoblot.

[28]. This A β ₄₂-RF fusion formed SDS-resistant low-n oligomers that reduced release factor activity, thus enhancing a read-through of stop codon mutations. Indeed, a correlation of oligomer formation and stop codon read-through was confirmed by biochemical analysis [28, 29]. An important distinction of this approach from previous anti-A β aggregation screens [30-32] is that we can detect drugs that inhibit A β ₄₂ oligomer formation but do not inhibit the formation of large A β ₄₂ amyloid. This is important because such large aggregates are now thought to be helpful because they likely capture some of the more toxic A β ₄₂ oligomers, rendering them less toxic [33, 34]

Here, we show that the mechanism of the PICALM, human AD risk factor, is likely to reduce the level of A β ₄₂ oligomers in cells. This strongly supports the hypothesis that oligomerization of A β ₄₂ is a major cause of AD toxicity. We then screened FDA-approved drugs that could readily be developed into Alzheimer's therapies, to identify drugs that prevent the formation of A β ₄₂ small oligomers using the yeast A β ₄₂-RF reporter system. We also showed that each of the drug hits counteract yeast and mammalian cell toxicity associated with A β ₄₂ small aggregates.

RESULTS

YAP1802, homolog of PICALM, inhibits A β ₄₂-RF oligomer formation

We tested whether genetic modifiers that rescue HDEL-A β ₄₂ toxicity [24] likewise repair the compromised A β ₄₂-RF translational termination factor activity due to reduced

A β ₄₂-RF oligomer formation using the above described growth assay [28, 29]. The cell growth phenotype in this assay requires expression of full length Ade1. The impaired Sup35 translational release factor (RF) activity of oligomerized A β ₄₂-RF allows read-through of the *ade1-14* premature stop codon enabling growth on adenineless media (-Ade) (A β ₄₂-RF-empty vector (e. v.) in Figure 1A). However in the presence of drugs or genetic modifiers blocking oligomerization of A β ₄₂-RF, or in cells expressing a fusion made with the A β ₄₂ aggregation-deficient mutation [28, 29], A β ₄₂m2-RF, the RF activity is restored, so cells cannot grow on -Ade (A β ₄₂m2-RF-empty vector (e. v.) in Figure 1A). Among the 12 genetic modifiers identified in the HDEL-A β ₄₂ screen [24], only cells expressing YAP1802 regained translational termination factor activity (shown as reduced growth on -Ade), suggesting it restored A β ₄₂-RF to the soluble monomeric state (Figure 1A). Indeed, immunoblots developed with Sup35C antibody showed that the level of SDS-resistant A β ₄₂-RF oligomer was significantly reduced, and the level of the monomers was significantly increased when Yap1802 was overexpressed (Figure 1B). Thus, YAP1802 is likely to affect toxicity by reducing the level of toxic A β ₄₂ oligomers.

We also used NAB61 antibody, which was reported to preferentially recognize toxic A β oligomers in AD patients [35] and HDEL-A β ₄₂ in yeast [24]. Indeed, while Sup35C antibody detected only monomers in A β ₄₂m2-RF cells expressing the A β ₄₂ aggregation-deficient mutation (Figure S1), NAB61 did not recognize A β ₄₂m2-RF monomers alt-




FIGURE 2: Dose-dependent effects of 8 drugs on A β ₄₂-RF activity as measured by cell growth. A β ₄₂-RF expressing cells were treated with each drug at the indicated concentrations. Their effects on cell growth were measured as OD₆₀₀ in +Ade and -Ade media after 4 and 5 days respectively (see Materials and Methods for details). Growth in -Ade is dependent upon A β ₄₂-RF release factor activity. This activity is expected to be reduced by oligomerization. Growth on +Ade does not require A β ₄₂-RF release factor activity and is used as a control in the presence of each drug. Shown is the relative growth in the presence vs. absence of each drug. Error bars show the standard deviation from three replicates. The asterisks show significance levels of **P < 0.01 or *P < 0.05 according to the Student's t test between DMSO (0) control and drug treatment at marked concentration for growth in -Ade.

though it detected a species the size of dimers. However, in our hands NAB61 recognized both oligomers and monomers of wild-type A β ₄₂-RF (Figure S1).

Screen for drugs that inhibit A β ₄₂-RF from forming toxic oligomers

We screened the Prestwick Chemical Library[®] (Prestwick Chemical, Washington, DC) which contains 1,200 FDA approved drugs and drug-like molecules for the ability to reduce A β ₄₂ oligomer formation using the growth assay described above [28, 29]. Drugs that blocked oligomerization of A β ₄₂-RF, thereby restoring the RF activity and preventing stop codon read-through, were selected as initial candidates because they reduced growth in -Ade.

Each assay was carried out in duplicate at a single compound concentration (20 μ M). The Z values [36] calculated from controls were 0.65 and 0.71 for the -Ade and +Ade assays, respectively, indicating the assay qualities were excellent. In the initial screen, 24 known drugs from among the 1,200 compounds in the library emerged as candidates that inhibited growth in -Ade medium without significant inhibition of growth in +Ade medium. When the results were repeated, 14 of the 24 drugs at 20 μ M in DMSO inhibited growth more than 50% in -Ade when compared to a no drug DMSO control (the 8 drugs in Figure 2 and the 6 drugs written in bold in Figure S2). The 6 hits shown in Figure S2 were dropped because they also decreased growth in +Ade medium by \geq 30% compared to the no drug control, indicating they are generally toxic to yeast, which invalidates our -Ade growth assay.

Dose-dependent inhibition of A β ₄₂-RF oligomerization

The 8 drugs that passed the confirmation screen were tested for dose-dependent effects on A β ₄₂-RF activity. The percent of relative growth in the presence of the drugs dissolved in DMSO was determined from the OD₆₀₀ (Figure 2). The A β ₄₂-RF control treated with DMSO only, showed good growth in -Ade, indicating A β -RF associated translational termination activity is compromised in the absence of drug due to oligomerization of the fusion protein. A β ₄₂m2-RF with DMSO had little or no growth in -Ade, indicating the mutant fusion protein was functional and not aggregated (Figures 1A and S1). In the presence of each drug, A β ₄₂-RF showed dose-dependent growth inhibition in -Ade, but no or mild growth inhibition in +Ade, indicating that the drugs block A β ₄₂-RF activity likely by blocking oligomerization.

We analyzed lysates prepared from cells grown with various concentrations (0-40 or 0-160 μ M) of each drug to test whether the restored translational termination factor activity associated with the drugs is correlated with a decrease in the level of SDS-resistant A β ₄₂-RF oligomers. In cells grown with DMSO only (the first lane marked 0 in each gel in immunoblots in Figure 3), there were mostly SDS-resistant A β ₄₂-RF oligomers (dimers, trimers and tetramers, etc.) and few monomers. Higher drug concentrations decreased the levels of oligomers and concomitantly increased the level of monomers, while the drugs have no effect on 3-phosphoglycerate kinase (PGK) expression at

any concentration. This inhibition of oligomer formation was quantified by comparing the ratios of oligomers to monomers detected on immunoblots of cell lysates grown in the presence or absence of drug (Figure 3 shows a representative sample from 3 independent experiments). Bromperidol, azaperone, haloperidol, pramoxine HCl, and dyclonine HCl exhibited strong anti-oligomer activity (Figure 3) as well as restored A β ₄₂-RF activity indicated by growth inhibition in -Ade at relatively low concentrations (Figure 2). Unexpectedly, minocycline HCl and tamoxifen citrate, that decreased growth in -Ade at 10-20 μ M and 5 μ M, respectively (Figure 2), only showed inhibition of oligomer formation at high concentrations, 160 and 80 μ M, respectively. Finally, ifenprodil tartrate that showed dose-dependent growth inhibition in -Ade failed to change the oligomer profile (Figure 3) and was dropped.

Importantly, the remaining 7 drugs enhanced the ability of A β ₄₂-RF, but not of a *SUP35* suppressor mutation (*G1256A* [37]), to terminate protein synthesis at the *ade1-14* nonsense mutation, as measured by growth on -Ade (Figure S3). Thus the drugs do not have a general antisuppressor activity, but instead specifically affect A β ₄₂-RF.

Drugs prevent A β ₄₂ from being toxic in PC12 cells

Some species of A β oligomers of various sizes and shapes prepared *in vitro* or purified from post mortem brains have been shown to be toxic when applied to neuronal cell culture or primary cortical neurons [38-41]. To test the activity of drugs in reducing A β ₄₂ oligomerization, we added the drugs as we assembled A β ₄₂ using *in vitro* conditions in which the aggregation of A β ₄₂ into small soluble oligomers was favored [38]. Treatment of rat PC12 neuronal cells with 20 μ M of A β ₄₂ assembled in the presence of DMSO decreased cell viability to about 40% (red bar in Figure 4A) compared to control cells treated with DMSO in the absence of A β ₄₂ (blue bar in Figure 4A), indicating that the assembled A β ₄₂ were indeed toxic. A β ₄₂ assembled in the presence of the remaining 7 hits from the Prestwick Chemical Library[®] were less toxic (Figure 4A), suggesting that the drugs impede the formation of the toxic A β ₄₂ assemblies. In addition, AO-11 and AO15, compounds that inhibit A β ₄₂-RF from forming oligomers, identified from our previous screen [28], also relieved toxicity.

Among drugs tested, minocycline HCl was the most effective. Cell viability increased from 40% when A β ₄₂ was assembled in DMSO alone, to 68% when it was assembled in the presence of 10 μ M minocycline HCl (Figure 4A). The minocycline HCl protection was dose-dependent (Figure 4B). Furthermore, treatment of PC12 cells with minocycline HCl without A β ₄₂ did not improve cell viability (Figure 4B). This suggests the protective effect of the minocycline HCl was not due to the enhancement of cell growth but rather was due to inhibition of A β ₄₂ toxicity.

Drugs do not affect *in vitro* A β ₄₂ fibril or oligomer formation

To test whether the drugs can also inhibit high molecular A β ₄₂ fibril formation, 4 of the most active drugs (bromperidol, tamoxifen citrate, minocycline HCl, and AO-11) were

added to 20 μM Aβ₄₂ at 50 μM, under conditions that promote fibrilization [42]. Fibrils were allowed to form for 5 or 72 hrs and the Thioflavine T (ThT) fluorescence assay was used to quantify fibril formation. At 5 hrs there was a mild inhibition of Aβ₄₂ fibrilization, but by 72 hrs there was no

significant change in fibrilization relative to the DMSO control (Figure 4C). Thus, while these drugs may have some effect on initial Aβ₄₂ small seed formation, they do not block fibril formation.




FIGURE 3: Seven drugs suppress Aβ₄₂-RF oligomerization in yeast in a dose-dependent manner. SDS-resistant Aβ₄₂-RF oligomers were detected by immunoblot analysis (upper). The assay strain expressing Aβ₄₂-RF was grown in complex medium in the presence of each compound at the indicated concentrations. Equal amounts of lysate proteins were treated with 1% SDS for 7 mins at room temperature and analyzed by SDS PAGE followed by immunoblotting with anti-Sup35 RF antibodies. Aβ₄₂-RF cells grown in DMSO (0) were used as controls. PGK, yeast 3-Phosphoglycerate Kinase, detected with anti PGK antibodies was an internal control to show the effect of the drugs on protein synthesis in general. Immunoblot signals for Aβ₄₂-RF monomers and oligomers were quantified and converted into % inhibition of oligomer formation from the ratios of oligomers to monomers compared to DMSO controls (0 means no inhibition) (lower). Error bars represent standard deviation from 3 independent immunoblots except for ifenprodil tartrate which shows data from 1 of 2 immunoblots that showed no drug effects. The asterisks show significant levels of **P < 0.01 or *P < 0.05 according to Student's t test.

We also tried to test the effects of bromperidol, azaperone, pramoxine HCl, dyclonine HCl, minocycline HCl and tamoxifen citrate when added to Aβ₄₂ during *in vitro* oligomerization conditions [38]. However, when these reactions were run on Western blots, only Aβ₄₂ the size of 12mers and larger were detected. Aβ₄₂ monomers and small oligomers were not seen and the drugs had no effect on this.

Tamoxifen citrate prevents early steps of Aβ₄₂ oligomerization *in vitro*

We used an *in vitro* labeled Aβ₄₂ oligomerization assay to

test the effects of the drugs on the early steps of monomer to oligomer conversion [43]. This assay takes advantage of the fluorescence self-quenching observed when tetramethylrhodamine (TMR) is covalently attached to the N-terminal lysine of Aβ₄₂ (TMR-K-Aβ₄₂) [43]. The loss of TMR fluorescence indicates self-association of Aβ₄₂ monomers into oligomers (e.g. dimers, trimers, etc.). Most of the drugs did not affect the formation of the early oligomers in this assay. They showed the same fluorescence changes as the control without drug (TMR-K-Aβ₄₂) (Figure 4D). In contrast, tamoxifen citrate strongly reduced TMR fluorescence, indicating the formation of early off-pathway oligomers




FIGURE 4: The protective effect of drugs on Aβ₄₂ induced cytotoxicity in PC12 cells. (A) Toxicity of Aβ₄₂ assembled under conditions favoring oligomer formation was reduced when assembly was done in the presence of drugs. Aβ₄₂ at 200 μM assembled under conditions favoring oligomer formation in the presence of 100 μM drug or DMSO was diluted and added to PC12 cells at a concentration of 20 μM Aβ₄₂ and 10 μM drug. Cell viability was assessed after 24 hrs growth at 37°C using the MTT assay. The percentage of viable cells is shown. Error bars are the standard deviation of triplicate experiments. **(B)** Dose-dependent effects of minocycline HCl on Aβ₄₂ associated cytotoxicity. Methods were as in (A). PC12 cells were treated with final concentrations of 20 μM Aβ₄₂ with 5, 10, and 15 μM minocycline HCl or DMSO only (blue bars). Cells were also treated with the indicated amount of minocycline HCl alone (red bars). **(C)** Effect of drugs on *in vitro* Aβ₄₂ high molecular fibril assembly in fibril favorable conditions. Aβ₄₂ was assembled into high molecular fibrils at 37°C in the presence of 50 μM drug or control DMSO according to [42]. Thioflavine T (ThT) was added to aliquots at the indicated times and fluorescence, indicative of fiber formation, was measured. **(D)** Effect of drugs on *in vitro* labeled Aβ₄₂ (TMR-K-Aβ₄₂) oligomerization. Reduced TMR fluorescence, which measures oligomerization, was recorded as a function of time immediately after dilution of the TMR-K-Aβ₄₂ with addition of 10 μM of each drug or DMSO for a negative control. The asterisks show significance levels of **P < 0.01 or *P < 0.05 according to Student's t test between DMSO control and drug treatment (A) and DMSO control and drug treatment at 5 hrs (C).

[43] that could be functional or non-functional oligomers.

Anti-Aβ₄₂-RF oligomer drugs reduce toxicity of HDEL-Aβ₄₂ in yeast

We next tested the effects of the 7 drugs we identified that impede Aβ₄₂-RF oligomerization (Figures 2 and 3) on HDEL-Aβ₄₂ toxicity. To do this we used a strain with a deletion of *ERG6* (L3340), which is critical for increased drug permeability. L3340 was transformed with a 2μ plasmid (pAG425 *GAL1::HDEL-Aβ₄₂*) carrying HDEL-Aβ₄₂ under the *GAL1* promoter. As previously reported for *ERG6* wild-type cells [24], we found that *erg6Δ* cells expressing HDEL-Aβ₄₂ were growth inhibited (middle in Figure S4) compared to controls transformed with an empty vector (top in Figure S4) and that the toxicity was suppressed by overexpressing *YAP1802* (bottom in Figure S4).

We measured growth in liquid to assay the effects of drugs that inhibit Aβ₄₂-RF oligomerization on the toxicity of this strain (Figure 5). Drugs at the indicated concentrations were added to yeast with the toxic HDEL-Aβ₄₂ construct or an empty vector control. Cells were diluted in media that did (SGAL-Leu) or did not (SR-Leu) induce expression of HDEL-Aβ₄₂. While controls carrying the empty vector grew well in both inducing and non-inducing media (dark green bars in Figure 5), growth of yeast induced to express the HDEL-Aβ₄₂ (black bar in Figure 5 left) was decreased by 65% compared to growth in non-inducing media (black bar in

right), verifying that HDEL-Aβ₄₂ caused cytotoxicity. Treatment with 10 and 20 μM bromperidol, haloperidol and minocycline HCl relieved the toxicity while higher drug concentrations were toxic. Treatment with azaperone, pramoxine HCl, tamoxifen citrate and dyclonine HCl showed a relatively strong effect of suppressing the toxicity HDEL-Aβ₄₂ (left panel Figure 5) while not having a significant effect on growth in the absence of HDEL-Aβ₄₂ (right panel Figure 5). However, we were unable to detect effects of drugs tested (azaperone, pramoxine HCl, dyclonine HCl and tamoxifen citrate) on the HDEL-Aβ₄₂ oligomerization. Possibly this is because oligomerization of HDEL-Aβ₄₂ was very different from the oligomerization of Aβ₄₂-RF, showing only HDEL-Aβ₄₂ monomers and trimers.

Antimycine A, a control that showed no effect on Aβ₄₂-RF oligomerization (Figure S5) was also unable to relieve toxicity of HDEL-Aβ₄₂. In addition, the other 15 drugs that initially passed the Aβ₄₂-RF growth inhibition screen, but that were later eliminated as candidates, all failed to rescue HDEL-Aβ₄₂.

DISCUSSION

Despite tremendous efforts, there are only a few drugs that mask or relieve the symptoms of AD. Furthermore, we do not have any medications that prevent, arrest or cure the disease (www.alz.org). Recent improved assays provide evidence for Aβ small oligomeric species in AD brains [7, 8,




FIGURE 5: The effect of drugs that inhibit Aβ₄₂-RF from forming oligomers on toxicity caused by overexpression of HDEL-Aβ₄₂ in yeast. Effects of 7 drugs on suppression of HDEL-Aβ₄₂ toxicity and general cell growth are shown. Yeast cells carrying either HDEL-Aβ₄₂ (HDEL-Aβ₄₂ strain) or an empty vector (control) grown overnight in non-inducing plasmid selective media (2% raffinose, SR-Leu) were normalized, diluted to 1 x 10⁵ cells/100 μl of media in each of 96 wells and further grown for 3 days in 2% galactose inducing media (SRGal-Leu) or 2% raffinose noninducing media (SR-Leu) in the presence of each drug at the indicated concentrations. Growth was measured as OD₆₀₀. Error bars show the standard deviation from three trials. The asterisks show increased relative growth with drug treatment compared to DMSO control (black bar in left panel) at significance levels of **P < 0.01 or *P < 0.05 according to Student's t test.

44]. While the cause of AD remains unknown, increasing evidence suggests that aggregation of the A β_{42} peptide into small oligomers plays an important role in disease progression [12, 15, 45]. This hypothesis is also supported by a yeast model [24] in which toxicity associated with expression of A β_{42} was suppressed by overexpression of YAP1802, the yeast homolog of PICALM, a previously known genetic AD risk factor [25, 46]. Furthermore, in this paper we show that overexpressing Yap1802 inhibits A β_{42} -RF aggregation into oligomeric species (Figure 1B). This provides strong support for the idea that inhibiting the initial production or aggregation of A β_{42} would be an effective treatment to prevent or slow disease onset.

One approach has been to prevent the production of A β peptide by inhibiting the secretases that cleave A β from the amyloid precursor protein [47, 48]. However, results of recent clinical trials of inhibitors of β - (LY2886721; [Eli Lilly and Company, 2013 press release](#)) and γ -secretases (Sema-gacestat; [Eli Lilly and Company, 2010 press release](#) and Avagacestat; [Bristol-Myers Squibb, 2012 press release](#)) have been disappointing. This makes the approach of inhibiting the formation of toxic A β oligomers of more interest.

Among a handful of drugs that appear to inhibit A β_{42} from forming toxic oligomers [6, 27, 32, 41, 49-53] in pilot studies, several have reached clinical trials. Indeed, trials of PBT1 (clioquinol), a metal chelator, which modulates affinity for Cu²⁺ and Zn²⁺ and inhibits metal-induced A β_{42} aggregation [6, 54, 55] were dropped because of side effects [56]. PBT2, a second generation of PBT1, was safe but demonstrated no significant effect on cognition or memory in the trial ([Pubmed Health, 2014](#)). Phase 2 trials of scyllo-inositol (ELND005), that targets the C-terminus of A β_{42} and neutralizes cell derived A β_{42} trimers [57], were completed with promising results ([Transition Therapeutics, Inc., 2014 news press](#)).

Finding good drug candidates through high-throughput screening (HTS) is a long and costly process and is often challenged by lack of an appropriate system, low hit rates with high false-positives and toxicity of compounds. In this study, we use a yeast cell-based HTS to identify compounds that inhibit the A β_{42} -RF oligomerization among a library composed of FDA approved marketed drugs or drug-like compounds. Eight drug candidates emerged from the HTS screen (Figure 2), and 7 were found to have anti-A β_{42} oligomeric properties in subsequent biochemical assays (Figure 3): 3 antipsychotics (bromperidol, haloperidol and azaperone), 2 anesthetics (pramoxine HCl and dyclonine HCl), tamoxifen citrate, and minocycline HCl. Furthermore, the anti-oligomeric activity in growing yeast, of each of these 7 drugs, increased with increased dosages. Among our 7 hits, bromperidol, haloperidol, and azaperone are in the same drug class: dopamine antagonists. Pramoxine HCl and dyclonine HCl are both anesthetics.

Since the drugs we identified are already used in humans to treat other diseases, their side effects are known to be tolerable. In addition, at least four of these drugs - bromperidol, haloperidol, azaperone, and minocycline HCl, pass the blood brain barrier. These are both hurdles that

eliminate most Alzheimer's drug candidates from further study. Thus epidemiological studies of Alzheimer incidence in patients that take these drugs is now warranted.

Importantly, we linked the A β_{42} -RF oligomers formed in yeast with a possible pathological toxic oligomer species of the HDEL-A β_{42} fusion that was directed to and disrupted normal cellular endocytic trafficking in yeast [24]. While Yap1802 restored endocytic trafficking function to signaling molecules perturbed by A β_{42} aggregates [24], and PICALM protected rat cortical neurons from toxicity of A β_{42} oligomers formed extracellularly [24], it was not clear how PICALM actually impacted A β toxicity. Here, by testing genetic modifiers of HDEL-A β_{42} toxicity for those that repair the compromised A β_{42} -RF translational termination factor activity we found that cells overexpressing YAP1802 regained translational termination factor activity, suggesting it restored A β_{42} -RF to the soluble monomeric state (Figure 1A). Indeed, overexpressed Yap1802 reduced the level of SDS-resistant A β_{42} -RF oligomer by more than 50% (Figure 1B), indicating that Yap1802 is likely to have a common role in aggregation and toxicity of A β_{42} .

As expected, the other anti-A β_{42} -RF oligomer drugs also rescued toxicity of HDEL-A β_{42} (Figure 5). In contrast, the other 11 modifiers of HDEL-A β_{42} activity (shown in Figure 1A) did not have any effects on the A β_{42} -RF system. This is not unexpected as these modifiers may affect secretion rather than oligomer formation of the peptide. Also all of the 7 anti-A β_{42} -RF oligomerization drugs had effects on toxicity of A β_{42} rat PC12 cells (Figure 4A) and another toxic yeast AD system (Figure 5). This validates the A β_{42} -RF system as a useful screen for Alzheimer's drugs.

In our study the relative effectiveness of each drug was not always consistent in different assays, leaving the most relevant assay to be determined. Minocycline HCl and tamoxifen citrate only suppressed A β_{42} -RF oligomerization at high concentrations (Figure 3), but had among the strongest effects on oligomer levels and toxicity (Figures 2-5). Furthermore, only tamoxifen citrate inhibited *in vitro* oligomerization of TMR-A β_{42} (Figure 4D), indicating that minocycline HCl and tamoxifen citrate may inhibit A β_{42} toxicity via distinct pathways.

It is interesting that minocycline HCl and tamoxifen citrate, which were identified as strong hits in this study, are already being used in clinical trials for other neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis and Huntington Disease ([ClinicalTrials.gov](#)). Furthermore, minocycline HCl is a semi-synthetic tetracycline antibiotic that effectively crosses the blood-brain barrier. It has been suggested that minocycline protects patients from brain damage by reducing inflammation in AD, related tauopathies and neurodegenerative diseases that are caused by misfolded proteins [58-61]. Tamoxifen is an antagonist of calmodulin, a major cellular calcium receptor and calcium dependent regulator of many cellular processes. Increased calcium level alters neuronal dysfunction and ultimately leads to cell death in AD brains, showing there is a connection between calcium and AD. We now suggest that minocycline HCl and tamoxifen citrate also have anti-A β_{42} oligomeric activity.

The recent detection of potential hybrid oligomers composed of A β and other neurodegenerative disease associated proteins such as α -synuclein, TDP-43 and PrP from human AD post mortem brains suggest that A β oligomers may act as a template for the aggregation of other proteins generating a secondary amyloidosis [14, 15, 62]. Thus, prevention of A β peptide aggregation into toxic oligomers could not only prevent AD, but might also remove oligomeric seeds that contribute to the progression of other neurodegenerative diseases.

Our results demonstrate the efficacy of the HTS screen for drugs that inhibit A β ₄₂-RF oligomer formation. Future determination of the cellular targets of the drug hits may aid drug discovery. Most importantly it remains to be determined if these drugs can inhibit A β ₄₂ from forming toxic oligomers in humans, thereby reducing Alzheimer symptoms.

MATERIALS AND METHODS

Yeast strains, media and plasmids

L3149 and L3150 [28], used to test the effects of drugs on A β ₄₂-RF oligomerization, are *SUP35* and *ERG6* disrupted versions of 74-D694 (*MATa ade1-14 ura3-52 his3-200 sup35 Δ ::LEU2 erg6 Δ ::TRP1*), respectively containing p1364 (pRS313, *CEN*, *URA3*, *CUP1::A β ₄₂-RF*) or p1541 (pRS313, *CEN*, *URA3*, *CUP1::A β ^{F19,20T/131P}-RF*). While p1364 carries the wild-type A β ₄₂ peptide fused with the M (middle) and RF (release factor) domains of Sup35 (i.e. lacking the N-terminal prion domain), called here A β ₄₂-RF, p1541 carries a F19T, F20T and I31P triple mutant A β ₄₂ peptide that is aggregation-deficient [29], called here A β ₄₂m2-RF.

To test the effects of drugs on HDEL-A β ₄₂ associated toxicity, we transformed an *ERG6* deleted strain, L3340, (*MATa ade1-14 ura3-52 leu2-3, 112 his3-200 erg6 Δ ::TRP1*) with a 2 μ gateway expression vector (pAG425 base, *LEU2*) carrying A β ₄₂ fused to the C-terminus of an ER retention signal (HDEL) expressed with the inducible *GAL1* promoter, called here HDEL-A β ₄₂. The plasmid was generated by transferring *HDEL-A β ₄₂* from the pAG305 *GAL1::HDEL-A β ₄₂* integrative vector [24] to pAG425GAL-*ccdB* (Addgene) using Gateway Technology [63].

The plasmids of 12 genes previously shown to suppress HDEL-A β ₄₂ toxicity [24] were kindly supplied by Susan Lindquist (Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Cambridge, MA). Each plasmid carries the yeast ORF under the control of the *GAL1* promoter on the single copy plasmid, pBY011 (*CEN*, *URA3*, *Amp^R*) [24, 63].

Media, cultivation and transformation procedures were standard [64]. Expression of A β ₄₂-RF and HDEL-A β ₄₂ were respectively driven by the copper-inducible *CUP1* promoter with 50 μ M CuSO₄ and the galactose inducible *GAL1* promoter with 2% galactose.

Growth assays for the primary screen and confirmation

The primary screen employed the Prestwick Chemical Library[®] of 1,200 FDA approved or drug-like small compounds (Prestwick Chemical). Assays for selection of compounds that reduce the level of A β ₄₂-RF oligomers were as described previously [28]. Drugs in DMSO were diluted to 20 μ M in assay media (2% dextrose without or with adenine + 50 μ M CuSO₄, respectively, for the -Ade or +Ade assay) inoculated with 1 x 10⁵ or 1 x 10⁴

cells/well, respectively, for the -Ade or +Ade assays. Each 384-well plate contained 32 positive (A β ₄₂m2-RF) and 32 negative (A β ₄₂-RF) controls with 0.2 μ l of DMSO. The OD₆₀₀ was measured after 5 days for -Ade and 4 days for +Ade plates incubated at room temperature with shaking (900 rpm). Each assay was performed in duplicate in clear flat-bottom 384-well plates (ScreenMates) using a Tecan Freedom EVO 200 liquid handling robot at the Research Resources Center at the University of Illinois, Chicago. Drug candidates that caused less than 50% and more than 70% growth in -Ade and +Ade, respectively, compared to growth in DMSO controls were selected for further analysis. Drug effects on A β ₄₂-RF oligomer formation were directly tested with SDS gel electrophoresis using 10% Mini-PROTEAN[®] TGX[™] precast gels (Bio-Rad) and immunoblot analysis as described previously [65]. To detect the amount of SDS-resistant small oligomers, lysates were treated with 1% SDS for 7 min at room temperature, subjected to immunoblot analysis, and probed with antibodies against Sup35's RF domain (BE4, developed by Viravan Prapapanich, a former post doc in our laboratory).

A β ₄₂ *in vitro* oligomerization and fibrilization

A β ₄₂ was polymerized using conditions favorable for the formation of A β ₄₂ small soluble oligomers [38] or fibrils [42]. For A β ₄₂ soluble oligomer formation, synthetic recombinant peptide (HFIP, Rpeptide) dissolved to 5 mM in anhydrous DMSO (Sigma) and sonicated was diluted to 200 μ M in PBS (20 mM NaH₂PO₄, 140 mM NaCl, pH 7.4) supplemented with 0.2% SDS and allowed to oligomerize for 24 hrs at 37°C without agitation, in the absence (DMSO control), or presence of 100 μ M drug. Finally, any high molecular A β ₄₂ aggregates formed were removed by a brief centrifugation at 2,000 rpm. For A β ₄₂ fibril formation, 50 μ M of each drug was added to 20 μ M A β ₄₂ peptide in Tris-buffered saline (25 mM Tris, 150 mM NaCl, pH 7.5) and incubated under A β ₄₂ fibrilization conditions [42]. Following incubation at 37°C for different lengths of time, 100 μ l of A β ₄₂ was aliquoted into a 96 well plate with 200 μ l of Thioflavine T (ThT) solution (7 μ l ThT, 50 μ M glycine, pH 7.1). Quantification of fibril formation was measured at 483 nm with excitation at 450 nm on a Spectra Max M5 plate reader (Molecular Devices).

PC12 cell toxicity

Treatment of rat PC12 neuronal cells with A β ₄₂ aggregates formed under the oligomerization condition described above in the presence of each drug and subsequent assays for cell viability were as described [41]. Briefly, PC12 cells, derived from rat adrenal medulla pheochromocytoma (American Type Culture Collection), were cultured in RPMI 1640 complete growth medium (ATCC) supplemented with horse serum and fetal bovine serum and grown to confluency at 37°C with 5% CO₂. Cells were plated in tissue culture-treated flat bottom 96-well plates (Corning) at 10,000 cells/well and allowed to attach overnight before adding A β ₄₂ aggregates. Following incubation of cells for 24 hrs, the MTT cell viability assay was used to determine cell toxicity (Roche Applied Science). Briefly, 10 μ l of MTT was added to each well and following incubation for 4 hrs at 37°C, 100 μ l of solubilization solution was added and incubated overnight at 37°C. Absorbance was then recorded at 570 nm.

Oligomerization of TMR-labeled A β ₄₂

As described previously [43] a stock solution of TMR-K-A β ₄₂ (42 μ M) in 4 M GdnCl was diluted to a final concentration of 1 μ M in PBS (pH 7.4) supplemented with 1 mM EDTA and 5 mM β -mercaptoethanol. Drugs (10 μ M) were added to the reaction. The fluorescence of TMR-K-A β ₄₂ was recorded as a function of time immediately after dilution of the TMR-A β ₄₂ in an Alphascan fluorometer (Photon Technology International), with excitation and emission monochromators set to 520 and 600 nm, respectively.

CONTRIBUTION

S.-K.P. and S.W.L. designed the overall experimental approach and wrote the paper. S.-K.P. performed most of the experiments. K.R. provided the compound libraries and prepared the robot liquid handling system for the HTS screen, and analyzed and placed the hits in chemical family groups. M.B. and M.V. helped with culturing and maintaining PC12 cells. All authors edited the manuscript.

ACKNOWLEDGMENTS

This work was supported by grants to S.W.L. from the Alzheimer's Association (IIRG-06-25468 and IIRG-10-173736) and the NIH (R21 AG02881). The authors are grateful to Dr. Susan Lindquist (MIT, Cambridge, MA), Dr. Arron Gitler (Stanford University, San Francisco, CA), and Dr. Virginia Lee (University of Pennsylvania, Philadelphia, PA) for kindly providing a yeast HDEL-A β ₄₂ toxic strain, plasmids carrying yeast ORFs under control of the GAL1 promoter, and NAB61 antibody respec-

tively. We also thank Dr. Andrew Mesecar (Purdue University, Indiana, IN) and Dr. Scott Pegan (University of Georgia, Athens, GA) for their ideas and helpful suggestions. Finally, we thank Dr. Kanchan Garai and Dr. Carl Frieden (Washington University School of Medicine, St. Louis, MO) for testing and providing data of in vitro assay for oligomerization of TMR-labeled A β ₄₂, which is shown in Fig. 4D.

SUPPLEMENTAL MATERIAL

All supplemental data for this article are available online at www.microbialcell.com.

CONFLICT OF INTEREST

The authors declare there is no conflict of interest.

COPYRIGHT

© 2016 Park *et al.* This is an open-access article released under the terms of the Creative Commons Attribution (CC BY) license, which allows the unrestricted use, distribution, and reproduction in any medium, provided the original author and source are acknowledged.

Please cite this article as: Sei-Kyoung Park, Kiira Ratia, Mariam Ba, Maria Valencik and Susan W. Liebman (2016). Inhibition of A β ₄₂ oligomerization in yeast by a PICALM ortholog and certain FDA approved drugs. **Microbial Cell** 3(2): 53-64. doi: 10.15698/mic2016.02.476

REFERENCES

- Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL (1998). Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. **Proc Natl Acad Sci U S A** 95(11): 6448-6453.
- McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999). Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. **Ann Neurol** 46(6): 860-866.
- Glabbe CG, Kaye R (2006). Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. **Neurology** 66(2 Suppl 1): S74-78.
- Dahlgren KN, Manelli AM, Stine WB, Jr., Baker LK, Krafft GA, LaDu MJ (2002). Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. **J Biol Chem** 277(35): 32046-32053.
- Yang T, Hong S, O'Malley T, Sperling RA, Walsh DM, Selkoe DJ (2013). New ELISAs with high specificity for soluble oligomers of amyloid beta-protein detect natural Abeta oligomers in human brain but not CSF. **Alzheimers Dement** 9(2): 99-112.
- Matlack KE, Tardiff DF, Narayan P, Hamamichi S, Caldwell KA, Caldwell GA, Lindquist S (2014). Clioquinol promotes the degradation of metal-dependent amyloid-beta (Abeta) oligomers to restore endocytosis and ameliorate Abeta toxicity. **Proc Natl Acad Sci U S A** 111(11): 4013-4018.
- Bruggink KA, Jongbloed W, Biemans EA, Veerhuis R, Claassen JA, Kuiperij HB, Verbeek MM (2013). Amyloid-beta oligomer detection by ELISA in cerebrospinal fluid and brain tissue. **Anal Biochem** 433(2): 112-120.
- Savage MJ, Kalinina J, Wolfe A, Tugusheva K, Korn R, Cash-Mason T, Maxwell JW, Hatcher NG, Haugabook SJ, Wu G, Howell BJ, Renger JJ, Shughrue PJ, McCampbell A (2014). A sensitive abeta oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid. **J Neurosci** 34(8): 2884-2897.
- Ono K, Condron MM, Teplow DB (2009). Structure-neurotoxicity relationships of amyloid beta-protein oligomers. **Proc Natl Acad Sci U S A** 106(35): 14745-14750.
- Lesne S, Koh MT, Kotilinek L, Kaye R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006). A specific amyloid-beta protein assembly in the brain impairs memory. **Nature** 440(7082): 352-357.
- Townsend M, Cleary JP, Mehta T, Hofmeister J, Lesne S, O'Hare E, Walsh DM, Selkoe DJ (2006). Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. **Ann Neurol** 60(6): 668-676.
- Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. **Nature** 416(6880): 535-539.
- Mudher A, Lovestone S (2002). Alzheimer's disease-do taoists and baptists finally shake hands? **Trends Neurosci** 25(1): 22-26.
- Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, Mizuno H, Spencer B, Rockenstein E, Trejo M, Platoshyn O, Yuan JX, Masliah E (2008). Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. **PLoS One** 3(9): e3135.
- Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (2009). Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. **Nature** 457(7233): 1128-1132.

16. Gitler AD (2008). Beer and bread to brains and beyond: can yeast cells teach us about neurodegenerative disease? **Neurosignals** 16(1): 52-62.
17. Tardiff DF, Khurana V, Chung CY, Lindquist S (2014). From yeast to patient neurons and back again: powerful new discovery platform. **Mov Disord** 29(10): 1231-1240.
18. Panaretou B, Jones GW (2014). Yeast models for amyloid disease. **Essays Biochem** 56(85-97).
19. Tribouillard D, Bach S, Gug F, Desban N, Beringue V, Andrieu T, Dormont D, Galons H, Laude H, Vilette D, Blondel M (2006). Using budding yeast to screen for anti-prion drugs. **Biotechnol J** 1(1): 58-67.
20. Bharadwaj P, Waddington L, Varghese J, Macreadie IG (2008). A new method to measure cellular toxicity of non-fibrillar and fibrillar Alzheimer's Abeta using yeast. **J Alzheimers Dis** 13(2): 147-150.
21. Caine J, Sankovich S, Antony H, Waddington L, Macreadie P, Varghese J, Macreadie I (2007). Alzheimer's Abeta fused to green fluorescent protein induces growth stress and a heat shock response. **FEMS Yeast Res** 7(8): 1230-1236.
22. von der Haar T, Josse L, Wright P, Zenthon J, Tuite MF (2007). Development of a novel yeast cell-based system for studying the aggregation of Alzheimer's disease-associated Abeta peptides in vivo. **Neurodegener Dis** 4(2-3): 136-147.
23. D'Angelo F, Vignaud H, Di Martino J, Salin B, Devin A, Cullin C, Marchal C (2013). A yeast model for amyloid-beta aggregation exemplifies the role of membrane trafficking and PICALM in cytotoxicity. **Dis Model Mech** 6(1): 206-216.
24. Treusch S, Hamamichi S, Goodman JL, Matlack KE, Chung CY, Baru V, Shulman JM, Parrado A, Bevis BJ, Valastyan JS, Han H, Lindhagen-Persson M, Reiman EM, Evans DA, Bennett DA, Olofsson A, Delager PL, Tanzi RE, Caldwell KA, Caldwell GA, Lindquist S (2011). Functional links between Abeta toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. **Science** 334(6060): 1241-1245.
25. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, Bis JC, Smith AV, Carassquillo MM, Lambert JC, Harold D, Schrijvers EM, Ramirez-Lorca R, Debette S, Longstreth WT, Jr., Janssens AC, Pankratz VS, Dartigues JF, Hollingworth P, Aspelund T, Hernandez I, Beiser A, Kuller LH, Koudstaal PJ, Dickson DW, Tzourio C, Abraham R, Antunez C, Du Y, Rotter JJ, et al. (2010). Genome-wide analysis of genetic loci associated with Alzheimer disease. **JAMA** 303(18): 1832-1840.
26. Lambert JP, Ivosev G, Couzens AL, Larsen B, Taipale M, Lin ZY, Zhong Q, Lindquist S, Vidal M, Aebbersold R, Pawson T, Bonner R, Tate S, Gingras AC (2013). Mapping differential interactomes by affinity purification coupled with data-independent mass spectrometry acquisition. **Nat Methods** 10(12): 1239-1245.
27. Macreadie I, Lotfi-Miri M, Mohotti S, Shapira D, Bennett L, Varghese J (2008). Validation of folate in a convenient yeast assay suited for identification of inhibitors of Alzheimer's amyloid-beta aggregation. **J Alzheimers Dis** 15(3): 391-396.
28. Park SK, Pegan SD, Mesecar AD, Jungbauer LM, LaDu MJ, Liebman SW (2011). Development and validation of a yeast high-throughput screen for inhibitors of Abeta42 oligomerization. **Dis Model Mech** 4(6): 822-831.
29. Bagriantsev S, Liebman S (2006). Modulation of Abeta42 low-n oligomerization using a novel yeast reporter system. **BMC Biol** 4(32).
30. Wright O, Zhang L, Liu Y, Yoshimi T, Zheng Y, Tunnacliffe A (2013). Critique of the use of fluorescence-based reporters in *Escherichia coli* as a screening tool for the identification of peptide inhibitors of Abeta42 aggregation. **J Pept Sci** 19(2): 74-83.
31. Hamaguchi T, Ono K, Murase A, Yamada M (2009). Phenolic compounds prevent Alzheimer's pathology through different effects on the amyloid-beta aggregation pathway. **Am J Pathol** 175(6): 2557-2565.
32. Necula M, Kaye R, Milton S, Glabe CG (2007). Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. **J Biol Chem** 282(14): 10311-10324.
33. Necula M, Breydo L, Milton S, Kaye R, van der Veer WE, Tone P, Glabe CG (2007). Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. **Biochemistry** 46(30): 8850-8860.
34. Chen J, Armstrong AH, Koehler AN, Hecht MH (2010). Small molecule microarrays enable the discovery of compounds that bind the Alzheimer's Abeta peptide and reduce its cytotoxicity. **J Am Chem Soc** 132(47): 17015-17022.
35. Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, Abel T, Lee VM (2006). Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. **The Journal of biological chemistry** 281(7): 4292-4299.
36. Zhang JH, Chung TD, Oldenburg KR (1999). A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. **J Biomol Screen** 4(2): 67-73.
37. Bradley ME, Bagriantsev S, Vishveshwara N, Liebman SW (2003). Guanidine reduces stop codon read-through caused by missense mutations in SUP35 or SUP45. **Yeast** 20(7): 625-632.
38. Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, Janson B, Bahr M, Schmidt M, Bitner RS, Harlan J, Barlow E, Ebert U, Hillen H (2005). Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. **J Neurochem** 95(3): 834-847.
39. Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, Yu J, Venton DL, Krafft GA, Finch CE, Klein WL (2001). Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. **J Neurochem** 79(3): 595-605.
40. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH (2005). Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. **Nat Neurosci** 8(1): 79-84.
41. McKoy AF, Chen J, Schubach T, Hecht MH (2012). A novel inhibitor of amyloid beta (Abeta) peptide aggregation: from high throughput screening to efficacy in an animal model of Alzheimer disease. **J Biol Chem** 287(46): 38992-39000.
42. Stine WB, Jr., Dahlgren KN, Krafft GA, LaDu MJ (2003). In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. **J Biol Chem** 278(13): 11612-11622.
43. Garai K, Frieden C (2013). Quantitative analysis of the time course of Abeta oligomerization and subsequent growth steps using tetramethylrhodamine-labeled Abeta. **Proc Natl Acad Sci U S A** 110(9): 3321-3326.
44. Benilova I, Karran E, De Strooper B (2012). The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. **Nat Neurosci** 15(3): 349-357.
45. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL (2007). Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. **J Neurosci** 27(4): 796-807.

46. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Belonguez C, DeStafano AL, Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thornton-Wells TA, Jones N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN, Kamatani Y, Lin CF, Gerrish A, Schmidt H, Kunkle B, Dunstan ML, Ruiz A, Bihoreau MT, Choi SH, Reitz C, Pasquier F, et al. (2013). Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. **Nat Genet** 45(12): 1452-1458.
47. Ganjei JK (2010). Targeting amyloid precursor protein secretases: Alzheimer's disease and beyond. **Drug News Perspect** 23(9): 573-584.
48. Zheng H, Koo EH (2006). The amyloid precursor protein: beyond amyloid. **Mol Neurodegener** 1(5).
49. Wang Y, Yin H, Wang L, Shuboy A, Lou J, Han B, Zhang X, Li J (2013). Curcumin as a potential treatment for Alzheimer's disease: a study of the effects of curcumin on hippocampal expression of glial fibrillary acidic protein. **Am J Chin Med** 41(1): 59-70.
50. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kaye R, Glabe CG, Frautschy SA, Cole GM (2005). Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. **J Biol Chem** 280(7): 5892-5901.
51. Feng Y, Wang XP, Yang SG, Wang YJ, Zhang X, Du XT, Sun XX, Zhao M, Huang L, Liu RT (2009). Resveratrol inhibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation. **Neurotoxicology** 30(6): 986-995.
52. Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, Engemann S, Pastore A, Wanker EE (2008). EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. **Nat Struct Mol Biol** 15(6): 558-566.
53. Nie Q, Du XG, Geng MY (2011). Small molecule inhibitors of amyloid beta peptide aggregation as a potential therapeutic strategy for Alzheimer's disease. **Acta Pharmacol Sin** 32(5): 545-551.
54. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI (2001). Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. **Neuron** 30(3): 665-676.
55. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL (2003). Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. **Arch Neurol** 60(12): 1685-1691.
56. Sampson EL, Jenagaratnam L, McShane R (2014). Metal protein attenuating compounds for the treatment of Alzheimer's dementia. **Cochrane Database Syst Rev** 2(CD005380).
57. Ma K, Thomason LA, McLaurin J (2012). scyllo-Inositol, preclinical, and clinical data for Alzheimer's disease. **Adv Pharmacol** 64: 177-212.
58. Garwood CJ, Cooper JD, Hanger DP, Noble W (2010). Anti-inflammatory impact of minocycline in a mouse model of tauopathy. **Front Psychiatry** 1(136).
59. Garwood CJ, Pooler AM, Atherton J, Hanger DP, Noble W (2011). Astrocytes are important mediators of Abeta-induced neurotoxicity and tau phosphorylation in primary culture. **Cell Death Dis** 2(e167).
60. Noble W, Garwood C, Stephenson J, Kinsey AM, Hanger DP, Anderson BH (2009). Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. **FASEB J** 23(3): 739-750.
61. Noble W, Garwood CJ, Hanger DP (2009). Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding. **Prion** 3(2): 78-83.
62. Guerrero-Munoz MJ, Castillo-Carranza DL, Krishnamurthy S, Paulucci-Holthausen AA, Sengupta U, Lasagna-Reeves CA, Ahmad Y, Jackson GR, Kaye R (2014). Amyloid-beta oligomers as a template for secondary amyloidosis in Alzheimer's disease. **Neurobiol Dis** 71: 14-23.
63. Alberti S, Gitler AD, Lindquist S (2007). A suite of Gateway cloning vectors for high-throughput genetic analysis in *Saccharomyces cerevisiae*. **Yeast** 24(10): 913-919.
64. Sherman F (2002). Getting started with yeast. **Methods Enzymol** 350: 3-41. doi.
65. Bagriantsev SN, Kushnirov VV, Liebman SW (2006). Analysis of amyloid aggregates using agarose gel electrophoresis. **Methods Enzymol** 412: 33-48.